Quick Summary
- Retatrutide is the most powerful incretin agonist ever developed — a triple-receptor agonist hitting GLP-1, GIP, and glucagon simultaneously, producing ~24-28% body weight loss in clinical trials.
- The core mechanism: appetite suppression via GLP-1, insulin sensitization via GIP, and direct energy expenditure via glucagon receptor activation — three independent fat-loss levers in one molecule.
- Who it’s for: serious fat loss candidates, body recomposition enthusiasts, and anyone running aggressive cutting protocols who wants the strongest single weekly injection available.
- Key differentiator: unlike semaglutide or tirzepatide, retatrutide adds glucagon agonism — meaning your body actively burns more energy at rest, not just eats less.
- Tony’s angle: retatrutide alone is incomplete. Stacked correctly on independent pathways (androgen, GH, thyroid, beta-3), you get fat loss with muscle preservation — the result every retatrutide-only user is missing.
The tony huge Retatrutide Synergy Protocol
Retatrutide alone hits ~24-28% body weight loss in trials. That’s already the strongest single molecule we’ve ever had. But the way I actually run it isn’t solo — it’s stacked on independent pathways so you keep muscle, accelerate fat oxidation, and offset the downsides retatrutide brings with it.
This is Law 5 — Independent Receptor Stacking applied to incretin therapy.
Deep Biochemistry — How Retatrutide Actually Works
Retatrutide is a single synthetic peptide that acts as a triple agonist on three different incretin and metabolic hormone receptors:
- GLP-1 receptor — drives satiety, slows gastric emptying, enhances glucose-dependent insulin secretion, reduces appetite at the hypothalamic level.
- GIP receptor — enhances insulin sensitivity, modulates adipose tissue function, works synergistically with GLP-1.
- Glucagon receptor — the differentiator. Increases hepatic glucose output, raises basal metabolic rate, drives direct energy expenditure.
Half-life ~6 days. Phase 2 TRIUMPH: 24.2% weight loss at 12mg/48 weeks. Phase 3 TRIUMPH-4: 28.7% at highest dose.
Tony Huge’s Law 5 — Independent Receptor Stacking
Different receptors operate on independent signaling pathways. Stacking compounds that hit DIFFERENT receptors is synergistic. Stacking compounds hitting the SAME receptor gives diminishing returns. Retatrutide already does this internally — three receptors in one molecule. This protocol extends Law 5 outward.
The Core Stack
Retatrutide — Dosing and Reconstitution
1mg per week for the first four weeks.
If your vial is 5mg, reconstitute with 1mL of bacteriostatic water. 20 units on a standard insulin needle (U-100) = 1mg. One pin per week.
If appetite isn’t significantly reduced after four weeks, titrate up: 1.5mg (30 units), then 2mg (40 units). Don’t chase trial-paper doses (8-12mg). Find your personal threshold.
The Synergistic Layers
AC-262 (Accadrine) — anti-catabolic androgen receptor layer. Retatrutide will eat your muscle if you let it. AC-262 binds the androgen receptor in muscle tissue with minimal androgenic spillover — safe for both sexes.
- Men: 20mg per day, any time
- Women: 10mg twice per week (Mon/Thu), any time
No meal timing required.
CJC-1295 with DAC — GH/IGF-1 axis. ½ vial (~1mg) once weekly, same day as retatrutide. DAC extension = sustained GH pulse for 6-8 days off one injection. One pin covers both compounds.
T3 — thyroid layer. 25mcg anytime in the morning. Keeps the metabolic ceiling from collapsing as appetite drops.
Mirabegron — beta-3 thermogenesis. 50mg once daily, any time. Activates brown adipose tissue. Independent from incretin, GH, and thyroid pathways. Half-life carries it through the day.
SLIN — glucose disposal. 2 caps with largest meals. Berberine + ALA + chromium + bitter melon + cinnamon. Hits AMPK + GLUT4 + insulin receptor sensitivity on three independent mechanisms.
The Stack at a Glance
| Pathway | Compound | Dose | Timing |
|---|---|---|---|
| GLP-1/GIP/Glucagon | Retatrutide | 1mg → titrate | Once weekly (20u insulin pin, 5mg @ 1mL recon) |
| Androgen receptor (M) | AC-262 | 20mg | Daily, anytime |
| Androgen receptor (F) | AC-262 | 10mg | 2x/week, anytime |
| GH/IGF-1 | CJC-1295 w/ DAC | ½ vial (~1mg) | Once weekly, same day as reta |
| Thyroid | T3 | 25mcg | Anytime AM |
| Beta-3 / BAT | Mirabegron | 50mg | Once daily, anytime |
| Glucose disposal | SLIN | 2 caps | With largest meals |
Timeline
| Timeframe | What to Expect |
|---|---|
| Week 1-2 | Mild appetite reduction. Mild GI adjustment. Mirabegron + T3 add thermogenic baseline lift. AC-262 pumps noticeable in the gym. |
| Week 4 | 3-5% bodyweight loss. Appetite suppression dialed in or dose titrated. CJC/DAC effects emerging: sleep, recovery, skin. Strength holding. |
| Week 8 | 8-12% bodyweight loss. Visible recomp. Energy stable. Bloodwork: improved lipids, glucose, A1c. |
| Week 12 | 15-20% range. Visual transformation point. Decision: continue, taper, or hold. |
What This Stack Delivers
8-12% body weight loss per month while gaining lean mass. Fat-specific loss with muscle preserved or growing. One pin per week (retatrutide + CJC-1295/DAC together). AC-262, mirabegron, T3 oral daily, no timing. SLIN with big meals.
Interesting Perspectives
The glucagon receptor is the underrated piece. Most retatrutide discussion focuses on appetite. But glucagon activation directly increases resting energy expenditure — more calories burned at baseline, all day. That’s why retatrutide users on the same caloric deficit as semaglutide users lose more fat.
Mirabegron is the dark horse compound of 2026. Originally for overactive bladder, beta-3 activation literally turns on the brown fat furnace. Beth Israel Deaconess research: 50mg daily increases BAT activity, improves insulin sensitivity, raises HDL.
AC-262 is the muscle preservation play that gets overlooked. Cleaner tissue selectivity than Ostarine or LGD-4033 — muscle preserved without the same HPG suppression. Light PCT requirements.
The once-weekly injection day. Retatrutide + CJC-1295/DAC in one pin. No daily peptide ritual.
Target Audience
- Men 30+ wanting body recomposition without losing gym progress
- Women seeking aggressive fat loss without masculinization risk
- Athletes prepping for contests, photo shoots, beach season
- People who tried semaglutide or tirzepatide and lost too much muscle
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” NEJM, 2023. DOI
- Rosenstock J, Frias J, Jastreboff AM, et al. “Retatrutide for type 2 diabetes: Phase 2 trial.” The Lancet, 2023.
- Cypess AM, et al. “Activation of human brown adipose tissue by a β3-adrenergic receptor agonist.” Cell Metabolism, 2015.
- Finan B, et al. “A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.” Nature Medicine, 2015.
- Teichman SL, et al. “Prolonged stimulation of GH and IGF-I secretion by CJC-1295.” JCEM, 2006.
- O’Mara AE, et al. “Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity.” JCI, 2020.
FAQ
What is retatrutide?
Once-weekly injectable peptide by Eli Lilly. Triple agonist on GLP-1, GIP, and glucagon receptors. ~24-28% body weight loss in trials.
How do I dose retatrutide?
Start 1mg/week for 4 weeks. 5mg vial + 1mL bac water = 20 units (insulin pin) per dose. Titrate up gradually if appetite suppression insufficient.
Side effects?
Nausea, constipation, reduced appetite (intended). Lower starting dose reduces GI severity. Bloodwork baseline + every 8-12 weeks.
Can I stack it?
Yes — with anything hitting different receptors. AC-262 (androgen), CJC-1295/DAC (GH), T3 (thyroid), mirabegron (beta-3), SLIN (AMPK/GLUT4). Law 5 stacking.
Who should use this?
Serious body recomp candidates wanting maximum fat loss with muscle preservation. Not for absolute beginners — requires injection technique, bloodwork discipline, monitoring.